Study: Zoledronic acid inhibits bone growth

04/25/2013 | AAFP News Now

Researchers found osteoporosis drug zoledronic acid increases levels of a biomarker that inhibits bone formation in postmenopausal women. The study was published in the Journal of Clinical Endocrinology & Metabolism. Lead author Antonino Catalano, M.D., said patients who use zoledronic acid may need other treatments to allow for new bone formation.

View Full Article in:

AAFP News Now

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC